摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[(2-Methylpropan-2-yl)oxycarbonyl]tetrazolo[1,5-a]pyrimidine-7-carboxylic acid | 916212-33-4

中文名称
——
中文别名
——
英文名称
5-[(2-Methylpropan-2-yl)oxycarbonyl]tetrazolo[1,5-a]pyrimidine-7-carboxylic acid
英文别名
——
5-[(2-Methylpropan-2-yl)oxycarbonyl]tetrazolo[1,5-a]pyrimidine-7-carboxylic acid化学式
CAS
916212-33-4
化学式
C10H11N5O4
mdl
——
分子量
265.228
InChiKey
IQRKXRUKLYVKAV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    120
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • Heterobicyclic metalloprotease inhibitors
    申请人:Steeneck Christoph
    公开号:US20070155738A1
    公开(公告)日:2007-07-05
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • Heterobicyclic Metalloprotease Inhibitors
    申请人:STEENECK Christoph
    公开号:US20090312312A1
    公开(公告)日:2009-12-17
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • HETEROBICYCLIC METALLOPROTEASE INHIBITORS
    申请人:Steeneck Christoph
    公开号:US20120015920A1
    公开(公告)日:2012-01-19
    The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
  • US7795245B2
    申请人:——
    公开号:US7795245B2
    公开(公告)日:2010-09-14
  • US8835441B2
    申请人:——
    公开号:US8835441B2
    公开(公告)日:2014-09-16
查看更多